Straight answer: device classification controls how much evidence you must generate—and that controls how fast (or slow) you reach market.

If you don’t understand your classification early, your timeline is not a plan. It’s a guess.

Under the framework of the U.S. Food and Drug Administration, medical devices are placed into three risk-based classes: Class I, Class II, and Class III. The higher the risk, the heavier the evidence burden—and the longer the timeline.

Let’s break down what that means in real terms.

Class I: Lowest Risk, Fastest Path (Usually)

Class I devices present minimal potential for harm.

Examples include basic surgical instruments and non-powered devices with well-understood risks.

What This Means for Timelines:

Often exempt from premarket submission

May only require general controls and quality system compliance

Limited testing burden

Typical timeline impact:

Months, not years

Lower development cost

Faster revenue entry

But don’t assume your device is Class I just because it looks simple. Intended use can escalate classification quickly.

Class II: Moderate Risk, Moderate Timeline

Most devices fall into Class II.

These require demonstration of safety and effectiveness—usually through the 510(k) pathway.

What This Means for Timelines:

Bench testing is required

Risk-based biocompatibility may be required

Software validation if applicable

Human factors evaluation in many cases

FDA review cycles apply

Typical timeline impact:

12–24 months from concept to clearance (depending on readiness)

Moderate regulatory spend

Iterative FDA interaction possible

Class II is manageable—but only if evidence is aligned correctly from the start.

Class III: Highest Risk, Longest Timeline

Class III devices sustain or support life, are implanted long-term, or present significant risk if they fail.

These require Premarket Approval (PMA).

What This Means for Timelines:

Extensive bench testing

Often animal studies

Well-controlled clinical trials

Comprehensive benefit-risk analysis

Longer FDA review periods

Typical timeline impact:

3–7+ years

Multi-million-dollar evidence programs

Significant investor dependence

At this level, classification doesn’t just affect timeline—it defines your capital strategy.

Why Classification Changes Everything

Device classification determines:

Type of submission required

Amount of preclinical testing

Need for clinical trials

Review timelines

Regulatory cost structure

Investor risk profile

If your classification is wrong, your timeline model is wrong.

And if your timeline model is wrong, your capital runway may be wrong too.

That’s how companies unexpectedly run out of money mid-development.

The Hidden Risk: Accidental Escalation

Common early decisions that escalate classification:

Expanding intended use claims

Targeting vulnerable populations

Adding therapeutic functionality

Incorporating novel materials or AI-based decision support

These changes may feel small technically.
Regulatorily, they can shift you from Class II to Class III.

That is not a minor adjustment. It is a strategic reset.

Where Kandih Comes In

This is where Kandih Group provides early clarity.

Kandih conducts structured classification assessments that:

Analyze intended use against FDA regulatory codes

Evaluate predicate device comparability

Identify technological risk escalators

Map classification to required evidence categories

Model realistic development timelines tied to risk level

Align timeline projections with capital planning

Instead of assuming a timeline, teams build one based on regulatory reality.

That prevents:

Forced pathway changes

Investor misalignment

Unexpected testing programs

Timeline collapse under diligence

Bottom Line

Device classification is not just a regulatory label.
It is a timeline controller.

Class I moves fastest.
Class II requires structured evidence.
Class III demands long-term capital and clinical proof.

Understanding your classification early protects time, money, and credibility.

That’s how Kandih helps founders build realistic, defensible paths to market—before engineering decisions harden.

References

FDA – Classify Your Medical Device
https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device

FDA – Premarket Notification 510(k)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-notification-510k

FDA – Premarket Approval (PMA)
https://www.fda.gov/medical-devices/premarket-submissions/premarket-approval-pma

FDA – De Novo Classification Process
https://www.fda.gov/medical-devices/premarket-submissions/de-novo-classification-request